Krka Generics Company Intelligence Report

Date: January 22, 2011
Pages: 16
Price:
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: KC2B72DA86DEN
Leaflet:

Download PDF Leaflet

Krka Generics Company Intelligence Report
Krka was established in Slovenia in 1954, and has grown to become one of the largest generic drug manufacturers in Central and Eastern Europe. With the acquisition of Lek
by Novartis in late 2002, Krka is now the only major Slovenian-owned pharmaceutical company.

Krka’s largest therapeutic category is cardiovascular drugs, followed by alimentary tract and metabolism, CNS and anti-infectives.

Krka Group reported sales worth 953.0 million euros (US$1,329.1 million) in 2009, a slight increase of 0.3% over 2008. Net profit stood at 173.7 million euros (US$242.2
million), an increase of 11.4% over 2008.

The domestic market accounted for 11.1% of total sales. Krka's Central European region was the largest, accounting for 28.1% of sales. This was followed by Eastern Europe, with 23.7%; Western Europe and Overseas, with 23.6%, and South-Eastern Europe, with 13.5% of total sales.

In 2007, Krka acquired the German firm, TAD Pharma. This represented the firm’s first takeover, giving the firm direct entry onto the German pharmaceutical market.

In June 2008, Krka became a minority owner of two Chinese pharmaceutical and chemical companies, gaining a 7.5% ownership share of both.

EXECUTIVE SUMMARY

INTRODUCTION

Krka Group: ten largest shareholders as of 31st December 2009
Krka Group development strategy
Krka: key strategies and objectives – to 2014
Krka: key strategies – to 2014
Krka: Group business objectives for 2010
PRODUCTS

Marketing authorisations
Krka Group: number of Marketing Authorisations by region, 2004 – 2009
Prescription pharmaceuticals
Krka Group: number of prescription pharmaceutical MAs by region, 2004 – 2009
Krka: new prescription pharmaceutical products introduced in 2009
Recent Product Approvals
CHMP adopts positive opinions for Krka's telmisartan
CHMP recommends authorisation of Krka's generic NovoNorm products

FINANCIAL RESULTS

Latest Interim Results, nine months 2010
Krka Group: consolidated nine month results, in euro 000s and US$000s
Krka Group: consolidated quarterly results, in euro 000s
Krka Group: consolidated quarterly results, in US$000s
Latest Fiscal Year Results – FY2009
Krka Group: fiscal year results, in euro 000s
Krka Group: fiscal year results, in US$000s
Results by Regions
Slovenia
South-Eastern Europe
Eastern Europe
Central Europe
Western Europe and Overseas Market
Krka Group: fiscal year results by region, in euro 000s
Krka Group: fiscal year results by region, in US$000s
Product and Service Groups
Krka Group: fiscal year results by product and service group, in euro 000s
Krka Group: fiscal year results by product and service group, in US$000s

MAJOR DEVELOPMENTS

Facilities
Slovenia
Krka opens refurbished Bršljin plant

CONTACT DETAILS
Skip to top


Zydus Cadila Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 12 pages
Egis Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 10 pages
Impax Generics Company Intelligence Report US$ 340.00 Jan, 2011 · 18 pages

Ask Your Question

Krka Generics Company Intelligence Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: